Published Paper Details:

Migraine is a common neurological disorder that significantly affects quality of life. Sumatriptan succinate a selective 5-hydroxytryptamine (5-HT1B/1D) receptor agonist, is widely used for the acute treatment of migraine; however, its oral administration is limited by low bioavailability and extensive first-pass metabolism. Mucoadhesive buccal drug delivery systems have emerged as a promising alternative due to their ability to enhance drug absorption, bypass hepatic metabolism, and improve therapeutic efficacy. This review comprehensively examines the role of mucoadhesive buccal drug delivery systems as a promising platform for the administration of sumatriptan succinate. Emphasis is placed on the formulation and evaluation of buccal films, immediate- and sustained-release delivery approaches, drug loading considerations, and their therapeutic implications in migraine management. In addition, current advancements, existing challenges, and future prospects in buccal delivery of sumatriptan succinate are discussed.